Rate My Professor Ross Wilson

University of Otago

5.0

1 review · out of 5

Rate Ross

Is this you? Claim this profile

Ratings & reviews

5.04/23/2026

Helps students see the bigger picture.

Taught by or worked with Ross?

Add your rating. It takes about 30 seconds.

About Ross

Dr. Ross Wilson is a Senior Research Fellow in the Centre for Musculoskeletal Outcomes Research (CMOR) within the Department of Surgical Sciences at the Dunedin School of Medicine, University of Otago. He holds a PhD in Economics from Lund University, Sweden, completed in 2016, and a Bachelor of Commerce with First Class Honours in Economics from the University of Otago in 2010. During his time at Lund University from 2011 to 2016, he worked as a Research Assistant in the Department of Economics from 2012 to 2015. Upon returning to New Zealand, Wilson joined the Department of Surgical Sciences at the University of Otago as a Post-doctoral Fellow from late 2015 to 2017, advanced to Research Fellow from 2018 to early 2023, and has served as Senior Research Fellow since February 2023.

Wilson's academic interests center on health economics, with a particular emphasis on the measurement and valuation of health-related quality of life, economic evaluations of healthcare interventions, and simulation modeling of disease epidemiology and treatment pathways to guide health policy decisions. His research predominantly addresses musculoskeletal conditions, including osteoarthritis, gout, chronic low back pain, multimorbidity, opioid use following joint arthroplasty, and cruciate ligament injuries. Notable publications include "Cost-effectiveness of low dose colchicine prophylaxis when starting allopurinol using the 'start-low go-slow' approach for gout: Evidence from a non-inferiority randomised double-blind placebo-controlled trial" (Arthritis Care & Research, 2025, with Pryymachenko, Dalbeth, Abbott, and Stamp); "Effectiveness of interventions for the management of multimorbidity in primary care and community settings: systematic review and meta-analysis" (Family Practice, 2025, with Lim, Al-Busaidi, Caya, Bricca, Mangin, and Abbott); "Validity of the Global Rating of Change in patients with chronic low back pain" (Musculoskeletal Science and Practice, 2025, with Pierobon, Fernandes, Christopherson, Stanley, Pryymachenko, Lim, Caya, Gayed, and Abbott); "Who should judge treatment effects as unimportant?" (Journal of Physiotherapy, 2023, with Shaheed, Mathieson, Furmage, and Maher); "Education plus exercise for persistent gluteal tendinopathy improves quality of life and is cost-effective compared with corticosteroid injection and wait and see: economic evaluation of a randomised trial" (Journal of Physiotherapy, 2023, with Mellor, Grimaldi, and Abbott); "Epidemiology of cruciate ligament injuries in New Zealand: exploring differences by ethnicity and socioeconomic status" (Injury Prevention, 2023); "The projected burden of knee osteoarthritis in New Zealand: healthcare expenditure and total joint replacement provision" (New Zealand Medical Journal, 2019); and "Development and validation of a new population-based simulation model of osteoarthritis in New Zealand" (Osteoarthritis and Cartilage, 2018). His contributions inform healthcare resource allocation and policy in New Zealand, particularly regarding the economic impacts of osteoarthritis and related interventions.